You are here
Pfizer’s Centers for Therapeutic Innovation Requests Proposals for Therapeutic Targets
Pfizer’s Centers for Therapeutic Innovation, or CTI, is a unique joint drug discovery model focused on collaborating with leading academic medical centers to rapidly translate novel target opportunities into new medicines.
Investigators can sign up to meet with a representative from Pfizer on April 9 to discuss their project fit prior to applying. Pre-registration is required and can be booked . If there are no available slots during Pfizer office hours, please reach out to firstname.lastname@example.org and we will coordinate a phone call.
CTI Collaborations Include
- Funded project-related research
- Hands-on collaboration from dedicated Pfizer drug-development experts
- Access to scientific/technological expertise and infrastructure at Pfizer
- Potential for financial incentives in the form of milestone and royalty payments
- Flexible publishing rights
- Opportunity for involvement in CTI’s Foundation collaborations
- Large Molecules: antibodies, proteins, fusion proteins, antibody conjugates, conditional activated biotherapeutics for enhanced tissue/tumor targeting
Areas of Interest
- Cancer – select solid tumors: colorectal, breast, lung, prostate, pancreatic, hepatocellular, ovarian cancers.
- Autoimmunity/Inflammation – inflammatory bowel disease, Non-alcoholic fatty liver disease/Non-alcoholic steatohepatitis, atopic dermatitis, psoriasis, Rheumatoid arthritis.
- Metabolic – cardiometabolism, cachexia.
- Rare – monogenic hematologic (non-malignant) disorders, neurologic/neuromuscular disorders, inborn errors of metabolism, endocrine, renal and cardiovascular diseases. Ultra-rare indications are not in scope at this time.
- DNA damage recognition and repair (e.g. replication stress or repair mechanisms)
- Tissue–resident immune modulation (e.g. adaptive or innate mechanisms, immunometabolism, etc.)
- Immune activators /enhancers (e.g. nucleic acid sensing, toll-like receptors etc)
- Modulation of senescence in cancer and non-neoplastic indications
- DNA repeat expansion diseases (e.g. Huntington’s disease, amyotrophic lateral sclerosis, myotonic dystrophy or frontotemporal dementia)
- Regulation of epithelial or mucosal barrier function including autophagy, host-microbe interactions
- Modulation of fibrosis pathways, either metabolism/stress-induced or inflammation-induced (possibly tumor-driven)
- Regulation of antigen-specific immune tolerance induction
- Emerging metabolic regulators in heart failure, satiety, nonalcoholic steatohepatitis and muscle biology
Pre-proposal Submission Process
Submission entails a non-confidential 2-3 page overview of the target, mechanism, evidence for disease linkage, and the proposed therapeutic drug. At a high level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic.
All researchers and clinicians whose work meets these criteria are invited to apply. Please submit non-confidential pre-proposals to your Technology Transfer Office by April 29th.
For further information about submitting a pre-proposal, please contact TechVentures@columbia.edu